FR14C0080I2 - Methode d'administration d'un anticorps - Google Patents

Methode d'administration d'un anticorps

Info

Publication number
FR14C0080I2
FR14C0080I2 FR14C0080C FR14C0080C FR14C0080I2 FR 14C0080 I2 FR14C0080 I2 FR 14C0080I2 FR 14C0080 C FR14C0080 C FR 14C0080C FR 14C0080 C FR14C0080 C FR 14C0080C FR 14C0080 I2 FR14C0080 I2 FR 14C0080I2
Authority
FR
France
Prior art keywords
antibody administration
antibody
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0080C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Millennium Pharmaceuticals Inc
Original Assignee
Genentech Inc
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Millennium Pharmaceuticals Inc filed Critical Genentech Inc
Publication of FR14C0080I1 publication Critical patent/FR14C0080I1/fr
Application granted granted Critical
Publication of FR14C0080I2 publication Critical patent/FR14C0080I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
FR14C0080C 2000-04-14 2014-11-13 Methode d'administration d'un anticorps Active FR14C0080I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55008200A 2000-04-14 2000-04-14
US09/748,960 US20010046496A1 (en) 2000-04-14 2000-12-27 Method of administering an antibody
PCT/US2001/012234 WO2001078779A2 (en) 2000-04-14 2001-04-13 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease

Publications (2)

Publication Number Publication Date
FR14C0080I1 FR14C0080I1 (OSRAM) 2014-12-19
FR14C0080I2 true FR14C0080I2 (fr) 2015-10-30

Family

ID=27069332

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0080C Active FR14C0080I2 (fr) 2000-04-14 2014-11-13 Methode d'administration d'un anticorps

Country Status (15)

Country Link
US (5) US20010046496A1 (OSRAM)
EP (3) EP1278543B1 (OSRAM)
JP (3) JP2003531129A (OSRAM)
AU (1) AU2001251629A1 (OSRAM)
BE (1) BE2017C009I2 (OSRAM)
CA (1) CA2406220C (OSRAM)
CY (3) CY1113489T1 (OSRAM)
DK (2) DK2298348T3 (OSRAM)
ES (2) ES2398096T3 (OSRAM)
FR (1) FR14C0080I2 (OSRAM)
LU (1) LUC00014I2 (OSRAM)
MX (1) MXPA02010059A (OSRAM)
NL (1) NL300702I2 (OSRAM)
PT (1) PT2298348T (OSRAM)
WO (1) WO2001078779A2 (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP3173426A1 (en) * 2002-02-25 2017-05-31 Biogen MA Inc. Administration of agents for the treatment of inflammation
HUE030806T2 (hu) * 2002-05-02 2017-05-29 Wyeth Holdings Llc Calicheamicin származék-hordozó konjugátumok
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SV2006001990A (es) 2004-01-09 2006-01-30 Pfizer Anticuerpos contra madcam
MX341370B (es) 2004-09-03 2016-08-17 Genentech Inc Antagonistas anti - beta7 humanizados y usos para los mismos.
CA2614314A1 (en) 2005-07-08 2007-01-18 Pfizer Limited Human anti-madcam antibodies
WO2007007152A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
MX2008000659A (es) * 2005-07-11 2008-03-13 Pfizer Ltd Nueva combinacion de anticuerpo contra madcam y de inhibidor de caspasa antifibrotico.
CN105037549B (zh) 2007-01-11 2018-09-28 诺和诺德公司 抗-kir抗体、制剂及其应用
WO2008115504A2 (en) * 2007-03-20 2008-09-25 Millennium Pharmaceuticals, Inc. Nucleic acids encoding humanized immunoglobulin that binds a4b7 integrin
US20110105724A1 (en) * 2007-08-16 2011-05-05 Stephanie Jane Clegg Novel compounds
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
MX2010012368A (es) * 2008-05-16 2010-12-06 Genentech Inc Uso de biomarcadores para evaluar un tratamiento contra trastornos inflamatorios gastrointestinales con antagonistas de beta7-integrina.
MX338969B (es) * 2009-03-20 2016-05-06 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
AU2011308496A1 (en) 2010-10-01 2013-05-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX384203B (es) * 2011-05-02 2025-03-14 Takeda Pharmaceuticals Co FORMULACION PARA ANTICUERPO ANTI -A4ß7.
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
MX366936B (es) * 2011-11-23 2019-07-31 Amgen Inc Uso de un anticuerpo específico alfa4beta7.
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
EA034583B1 (ru) * 2012-01-12 2020-02-21 Милленниум Фармасьютикалз, Инк. ПРИМЕНЕНИЯ АНТИ-α4β7 АНТИТЕЛА
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015518816A (ja) 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 腫瘍学関連タンパク質およびペプチドの産生のための修飾ポリヌクレオチド
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
BR112018068628A2 (pt) 2016-03-14 2019-07-30 Millennium Pharm Inc método de prevenção de doença do enxerto contra hospedeiro
BR112018068625A2 (pt) 2016-03-14 2019-07-30 Millennium Pharm Inc métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
EP3433275A1 (en) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
EP3452070A1 (en) 2016-05-04 2019-03-13 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating inflammatory bowel disease
MA45245A (fr) 2016-06-12 2019-04-17 Millennium Pharm Inc Méthode de traitement de maladie intestinale inflammatoire
AR112336A1 (es) 2017-07-14 2019-10-16 Pfizer ANTICUERPOS CONTRA MAdCAM
US20230139938A1 (en) * 2021-09-21 2023-05-04 University Of South Carolina Anti-CCL8 Antibodies and Treatment of Lung Injury by CCL8 Inhibition
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) * 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU675916B2 (en) * 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
EP0682529B2 (en) * 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
IL141877A0 (en) * 1998-09-14 2002-03-10 Biogen Inc Pharmaceutical compositions containing alpha4 integrin antagonists

Also Published As

Publication number Publication date
ES2398096T3 (es) 2013-03-13
LUC00014I1 (OSRAM) 2017-04-18
BE2017C009I2 (OSRAM) 2017-09-22
WO2001078779A3 (en) 2002-07-04
HK1054320A1 (en) 2003-11-28
EP2298348B1 (en) 2016-10-12
WO2001078779A2 (en) 2001-10-25
MXPA02010059A (es) 2004-08-19
US20140186345A1 (en) 2014-07-03
EP2298348A1 (en) 2011-03-23
CY2014046I1 (el) 2016-04-13
AU2001251629A1 (en) 2001-10-30
EP1278543B1 (en) 2012-09-19
NL300702I1 (OSRAM) 2016-01-28
EP1278543A2 (en) 2003-01-29
US20050095238A1 (en) 2005-05-05
CY2014046I2 (el) 2016-04-13
US20120034243A1 (en) 2012-02-09
PT2298348T (pt) 2017-01-04
CA2406220A1 (en) 2001-10-25
EP3167902B1 (en) 2020-07-29
ES2609689T3 (es) 2017-04-21
LUC00014I2 (OSRAM) 2017-06-19
CY1113489T1 (el) 2016-04-13
EP2298348B9 (en) 2017-02-15
JP5764524B2 (ja) 2015-08-19
CA2406220C (en) 2019-02-12
JP2003531129A (ja) 2003-10-21
EP3167902A1 (en) 2017-05-17
JP6021959B2 (ja) 2016-11-09
CY1118429T1 (el) 2017-06-28
DK2298348T3 (en) 2017-01-30
JP2015083603A (ja) 2015-04-30
NL300702I2 (OSRAM) 2016-01-28
US20010046496A1 (en) 2001-11-29
FR14C0080I1 (OSRAM) 2014-12-19
US20200002423A1 (en) 2020-01-02
DK1278543T3 (da) 2013-01-14
JP2012184241A (ja) 2012-09-27

Similar Documents

Publication Publication Date Title
FR14C0080I2 (fr) Methode d'administration d'un anticorps
CY2013011I1 (el) Μεθοδος χορηγησης διφωσφονικων
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
DE60121953D1 (de) Herstellungsverfahren von arzneizubereitungen
PT1253932E (pt) Composicoes farmaceuticas de toxina botulinica
EP1396500A4 (en) ANTI-TRAIL-R ANTIBODIES
IS5245A (is) Lyfjablanda úr ómeprasól
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
CY2014003I2 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
NO20071303L (no) Farmasoytiske preparater
EP1423431A4 (en) ANTIBODIES TO VLA-1
CY2007029I1 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
NO20025450L (no) Ny farmasöytisk sammensetning
EE200200393A (et) Glüburiidi ravimkoostis
IS6688A (is) Lyfjafræðilegar samsetningar af kólesterýl ester flutningspróteinhindrum
ID30187A (id) Dongkrak jenis pantagraf
EP1423399A4 (en) HYDROXYPYRIDONATE AND HYDROXYPYRIMIDINONE CHELATIZING AGENTS
EP1399187A4 (en) APPLICATIONS OF MONOCLONAL ANTIBODY 8H9
EP1542721A4 (en) MODIFIED "S" ANTIBODIES
DE60126814D1 (de) Inhalation von stickoxid
EE200300218A (et) Latentse antitrombiin III valmistamise meetod
ITBO20000446A0 (it) Unita' e metodo di trasferimento di spezzoni di sigaretta .
FR2816843B1 (fr) Inhibiteurs de l'enzyme 5 alpha-reductase
DE60142051D1 (de) Herstellung von perfluorolefinen
DE60132362D1 (de) Herstellung von ultradünnwandigen cordierit-strukturen